AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Clinical trials in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis) require histologic scoring for assessment of inclusion criteria and endpoints. However, variability in interpretation has impacted clinical trial outcomes. We developed an artificial intelligence-based measurement (AIM) tool for scoring MASH histology (AIM-MASH). AIM-MASH predictions for MASH Clinical Research Network necroinflammation grades and fibrosis stages were reproducible ( κ = 1) and aligned with expert pathologist consensus scores ( κ = 0.62–0.74). The AIM-MASH versus consensus agreements were comparable to average pathologists for MASH Clinical Research Network scores (82% versus 81%) and fibrosis (97% versus 96%). Continuous scores produced by AIM-MASH for key histological features of MASH correlated with mean pathologist scores and noninvasive biomarkers and strongly predicted progression-free survival in patients with stage 3 ( P < 0.0001) and stage 4 ( P = 0.03) fibrosis. In a retrospective analysis of the ATLAS trial (NCT03449446), responders receiving study treatment showed a greater continuous change in fibrosis compared with placebo ( P = 0.02). Overall, these results suggest that AIM-MASH may assist pathologists in histologic review of MASH clinical trials, reducing inter-rater variability on trial outcomes and offering a more sensitive and reproducible measure of patient responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Janani et al. introduced an AI driven scoring instrument for MASH histology whose assessments of necrosis, inflammatory grade and fibrosis stage were concordant with consensus pathologist evaluations [226].”
From Constructing biomimetic microenvironments for liver regeneration (2025) · doi:10.1186/s12951-025-03729-9 · cites this paper as [226]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 3×
“Summaries of each model and their respective objectives are included in Supplementary Table 6, and detailed descriptions of each model’s purpose, input and output, as well as training parameters, can be found in Supplementary Tables 7–9.”
Self-citationImproving neural networks by preventing co-adaptation of feature detectors
Hinton, G. E., Srivastava, N., Krizhevsky, A., Sutskever, I., & Salakhutdinov, R. R. (2012) · arXiv · doi:10.48550/arxiv.1207.0580 · Cited by 6,382 · cited 1×
“The artifact, H&E tissue and MT tissue CNNs were trained using pathologist annotations comprising 8–12 blocks of compound layers with a topology inspired by residual networks and inception networks with a softmax loss 44–46 .”
mixup: Beyond Empirical Risk Minimization
Zhang, H., Cisse, M., Dauphin, Y. N., & Lopez-Paz, D. (2017) · arXiv · doi:10.48550/arxiv.1710.09412 · Cited by 5,831
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationSpatial Pyramid Pooling in Deep Convolutional Networks for Visual Recognition
He, K., Zhang, X., Ren, S., & Sun, J. (2014) · Lecture Notes in Computer Science · doi:10.1007/978-3-319-10578-9_23 · Cited by 3,034
Powell, E. E., Cooksley, G. W. E., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990) · Hepatology · doi:10.1002/hep.1840110114 · Cited by 1,473
RhizoDB: A Bounded Activation-Flow Architecture for Graph-Based Memory Systems
Guberte, J. A. (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.20695702 · Cited by 866
Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology · doi:10.1002/hep.29514 · Cited by 549
Self-citationCaldwell, S. H., & Crespo, D. M. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.02.013 · Cited by 501
Research works printed but not linked: 5
- Pedregosa, F., Bach, F. & Gramfort, A. On the consistency of ordinal regression methods. J. Mach. Learn. Res. 18, 1–35 (2017).
- Iyer, J. S. et al. Artificial intelligence-based measurement of NASH histology (AIM-NASH) recapitulates primary results from phase 3 study of resmetirom for treatment of NASH/MASH. Hepatology 79, E56–E57 (2023).
- Cable, E. E., McWherter, C. A., Choi, Y. J., Shah, S. & Carrasco-Zevallos, O. M. Quantitative assessment of NASH pathologies in 152 baseline H&E slides from a phase 2 trial using the PathAI machine learning algorithm. NASH-TAG Proceedings 5, 5 (2021).
- Shevell, D. E. et al. Comparison of manual vs. machine learning approaches to liver biopsy scoring for NASH and fibrosis: a post-hoc analysis of the FALCON 1 study. Hepatology 74, 1415A (2021).
- Krizhevsky, A., Sutskever, I. & Hinton, G. ImageNet classification with deep convolutional neural networks. in Advances In Neural Information Processing Systems (eds Pereira, F., et al.) vol. 25 (Curran Associates, 2012).
Cited by
Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., Ramirez, B. I., Sánchez-Guirales, S. A., Simon, J. A., Tomietto, G., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101328 · Cited by 488
Pulaski, H., Harrison, S. A., Mehta, S. S., Sanyal, A. J., Vitali, M. C., Manigat, L. C., Hou, H., Christudoss, S. P. M., Hoffman, S. M., Stanford-Moore, S. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03301-2 · Cited by 84
Self-citationDecoding organ fibrosis: mechanistic insights and emerging therapeutic strategies
Chen, X., Zhang, J., Guo, L., Wu, C., Zhou, J., Xu, M., Mo, L., Li, Y., & He, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02532-0 · Cited by 58
Crucial functions of gut microbiota on gut–liver repair
Wang, Y., Yan, H., Zheng, Q., & Sun, X. (2025) · hLife · doi:10.1016/j.hlife.2025.01.001 · Cited by 42
Wong, V. W., Amin, N. B., Takahashi, H., Darekar, A., Tacke, F., Kiszko, J., Rodriguez, H., Nakajima, A., Alkhouri, N., Charlton, M., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00128-1 · Cited by 39
Metadata
- Authors
- Iyer, J. S., Juyal, D., Le, Q., Shanis, Z., Pokkalla, H., Pouryahya, M., Pedawi, A., Stanford-Moore, S. A., Biddle-Snead, C., Carrasco-Zevallos, O., Lin, M., Egger, R., Hoffman, S., Elliott, H., Leidal, K., Myers, R. P., Chung, C., Billin, A. N., Watkins, T. R., Patterson, S. D., Resnick, M., Wack, K., Glickman, J., Burt, A. D., Loomba, R., Sanyal, A. J., Glass, B., Montalto, M. C., Taylor-Weiner, A., Wapinski, I., & Beck, A. H.
- Affiliations
- PathAI (United States) (US)
- Harvard University (US)
- Gilead Sciences (United States) (US)
- Rhode Island Hospital (US)
- Newcastle University (GB)
- University of California San Diego (US)
- Virginia Commonwealth University (US)
- Amgen (United States) (US)
- Corresponding author
- Beck, Andrew H.
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-08-07
- Volume
- 30
- Issue
- 10
- Pages
- 2914-2923
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11485234
- OpenAlex
- W4401397580
- Cited by
- 54
- References
- 45
- Citations by year
- 2026: 23 · 2025: 25 · 2024: 6
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- National Institutes of Health (UL1TR001442)
- National Institute on Alcohol Abuse and Alcoholism (U01AA029019)
- National Heart, Lung, and Blood Institute (P01HL147835)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK124318, R01DK121378, R01DK106419, P30DK120515, U01DK061734, U01DK130190)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- artificial intelligence, histologic scoring, nonalcoholic steatohepatitis, liver fibrosis, clinical trial endpoints, interobserver variability, ATLAS trial, progression-free survival, liver disease
- MeSH terms
- Artificial Intelligence, Automation, Clinical Trials as Topic, Female, Humans, Liver Cirrhosis, Liver Diseases, Male, Retrospective Studies, Reproducibility of Results, Patient Selection, Endpoint Determination, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases. https://app.cochat.ai/papers/10.1038/s41591-024-03172-7
- The paper
- Iyer, J. S., Juyal, D., Le, Q., Shanis, Z., Pokkalla, H., Pouryahya, M., Pedawi, A., Stanford-Moore, S. A., Biddle-Snead, C., Carrasco-Zevallos, O., Lin, M., Egger, R., Hoffman, S., Elliott, H., Leidal, K., Myers, R. P., Chung, C., Billin, A. N., Watkins, T. R., . . . Beck, A. H. (2024). AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases. Nature Medicine. https://doi.org/10.1038/s41591-024-03172-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.